The Sierra Oncology Inc. (NASDAQ:SRRA) is going up by 3.67% in today’s trading session, a rise equivalent to 0.01% of the stock’s price from yesterday’s market close. A news came out on 11/07/19 stating that (PR) Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants by WSJ. The lowest point that the shares touched during the trading session was $0.2501, while the peak of the day was recorded at a share price of $0.29. SRRA finished the previous session at $0.25 according to the data provided by Barchart, while the trading volume was observed to be $1119748.

In the 100 days of trading, SRRA managed to top a 0.44% Moving average. Additionally, Sierra Oncology Inc. shares have achieved a 52-week range between 0.25 and 2.01 alongside 100 days raw stochastic set at 2.29%.

The number of shares outstanding, according to the fundamentals of the company, is set at 74.69M, equal to the value of $18.70M in market capitalization. In the last 30 days, Sierra Oncology Inc. shares went down by -27.89%, adding 0.36 to growth in value, on top of a +3.84% boost since 10/08/19.

Sierra Oncology Inc. (NASDAQ:SRRA) Analyst’s Estimates

Sierra Oncology Inc. (SRRA) could record at least -$0.21 per share in quarterly earnings in the upcoming report on 02/27/2020, a number that would actually represent a decrease of -0.91 YOY.

According to the average analyst rating, Sierra Oncology Inc. would be rated as Buy. Out of 2 different analysts monitoring SRRA stock, 2 analysts rate the stock as a BUY, 0 suggest to give the rating of HOLD, 0 indicate that SRRA is an OVERWEIGHT, 0 rated the stock as a SELL, and 0 analyst believes that the stock should be rated as UNDERWEIGHT.

On October 23, 2017, the stock earned a Upgrade rating due to a new analyst call from Jefferies, while analysts from SunTrust believe that the stock is set at Buy from Hold, as concluded on March 10, 2017. Wedbush, is still rather wary about the stock, deciding to keep the rating at Outperform as confirmed through a call on February 22, 2017.

SRRA Key Ratios To Watch:

The firm is also showcasing profitability through returns on assets in the company’s ownership, with ROA set at -50.40%. Beta value of the stock is recorded at 1.23. Additionally, Sierra Oncology Inc. is recording price volatility of 10.31% for the period of the last seven days and 9.51% in the last 30 days.

Sierra Oncology Inc. (NASDAQ:SRRA) Technical Outlook

For the period of the last 50 days, Sierra Oncology Inc. had its Raw Stochastic average set at 4.17% for the latest technical analysis. In comparison to the period of the last 20 days, the present Raw Stochastic average for the last 50 days poses as improvement, set at 8.73%. Stochastic %K for Sierra Oncology Inc., with the last 20 days included, was set at 30.38%, having Stochastic %D topping 47.23%. Based on the previous performance of the company for the mentioned period, there are more than several recorded moving trends. When it comes to the period of the last 12 months, accounting the time for year-to-date, price performance appears to be discouraging for Sierra Oncology Inc. stocks with recording -81.03% in metrics.

Sierra Oncology Inc. Insider Watch:

Similarly, 68.08% of the company’s float is held by institutions – and there are 63 institutions in total holding shares of this company. The top three institutional holders of SRRA stocks are: Frazier Management LLC with ownership of $4.0 million, which is approximately 8112121 of the company’s shares; New Leaf Venture Partners, L.l.c., holding 5020446 shares of the stock with an approximate value of $2.0 million; and Mangrove Partners, currently with more than 3688609 shares of the company valued at $2.0 million. Positions in Sierra Oncology Inc. stocks held by institutional investors has been changing actively in the past six months, a period during which there were 0 insider purchases amounting to 0 shares.